---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-26-000004"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:23:53.921799+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways secures $150M loan from Hercules Capital, $50M funded immediately

## Summary
- New $150M term loan facility with Hercules Capital; $50M drawn on Jan 5, 2026 (Tranche 1).
- Proceeds repay ~$31.1M existing debt; remaining funds for general corporate purposes.
- Interest rate of 9.75% or prime+2.75%; interest-only payments until Q1 2029, maturity Jan 5, 2031.
- Additional tranches up to $100M available upon clinical, FDA approval, and commercial milestones.
- Loan secured by personal property (excluding IP); prepayment penalties from 0.5% to 2.0%.

## SEC filing metadata
- accession: 0001816590-26-000004
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000004/0001816590-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000004/cmps-20260105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-26-000004
- JSON: https://secwatch.observer/filing/0001816590-26-000004.json
- Plain text: https://secwatch.observer/filing/0001816590-26-000004.txt

## Key facts
- Debt Financings
  COMPASS Pathways plc incurred term loan of $150,000,000 with Hercules Capital, Inc. at the greater of (i) 9.75% or (ii) 2.75% plus the Wall Street Journal prime rate maturing January 5, 2031.
  - Instrument: term loan
  - Principal: $150,000,000
  - Counterparty: Hercules Capital, Inc.
  - Rate: the greater of (i) 9.75% or (ii) 2.75% plus the Wall Street Journal prime rate
  - Maturity: January 5, 2031
  - Event: incurrence
  source text: The Amended Loan Agreement provides for five tranches of term loans in an aggregate principal amount of up to $150,000,000, consisting of (i) a term loan of $50.0 million which will be fully funded at the Closing Date (the “Tranche 1 Advance”), (ii) term loans of up to $30.0 million subject to the Borrowers achieving a clinical milestone and satisfying certain other conditions (the “Tranche 2 Advance”), (iii) term loans of up to $30.0 million subject to the Borrowers achieving a milestone relating to certain FDA approvals being granted and satisfying certain other conditions (the “Tranche 3 Advance”), (iv) term loans of up to $20.0 million subject to the Borrowers achieving a commercial milestone and satisfying certain other conditions (the “Tranche 4 Advance”), and (v) up to $20.0 million, subject to the approval of Hercules’ investment committee, as may be increased by any unborrowed amounts of the Tranche 2 Advance, the Tranche 3 Advance and the Tranche 4 Advance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000004/0001816590-26-000004-index.htm
- Material Agreements
  COMPASS Pathways plc amended Third Amendment with Hercules Capital, Inc. valued at up to $150,000,000 (effective 2026-01-05).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: up to $150,000,000
  - Effective: 2026-01-05
  source text: On January 5, 2026 (the “Closing Date”), COMPASS Pathways plc (the “Company”) and certain of its subsidiaries (together with the Company, the “Borrowers”) entered into the third amendment (the “Third Amendment”) to that certain loan and security agreement with Hercules Capital, Inc. (“Hercules”), dated as of June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000004/0001816590-26-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.